Abbott Laboratories (ABT) Shares Sold by Henderson Group PLC
Henderson Group PLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,423 shares of the healthcare product maker’s stock after selling 6,489 shares during the period. Henderson Group PLC’s holdings in Abbott Laboratories were worth $7,164,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the stock. Krilogy Financial LLC increased its stake in shares of Abbott Laboratories by 9.3% in the second quarter. Krilogy Financial LLC now owns 2,685 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 229 shares during the last quarter. SeaBridge Investment Advisors LLC increased its stake in shares of Abbott Laboratories by 10.6% in the second quarter. SeaBridge Investment Advisors LLC now owns 2,875 shares of the healthcare product maker’s stock valued at $113,000 after buying an additional 275 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Abbott Laboratories during the second quarter valued at $120,000. Bellwether Investment Group LLC acquired a new stake in shares of Abbott Laboratories during the second quarter valued at $145,000. Finally, Delta Asset Management LLC TN increased its stake in shares of Abbott Laboratories by 2.8% in the second quarter. Delta Asset Management LLC TN now owns 3,695 shares of the healthcare product maker’s stock valued at $146,000 after buying an additional 100 shares during the last quarter. 72.01% of the stock is owned by institutional investors and hedge funds.
Shares of Abbott Laboratories (NYSE:ABT) opened at 40.93 on Friday. The firm’s 50-day moving average price is $39.02 and its 200 day moving average price is $41.15. The company has a market cap of $60.26 billion, a PE ratio of 44.68 and a beta of 0.92. Abbott Laboratories has a 12 month low of $36.00 and a 12 month high of $45.79.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 19th. The healthcare product maker reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.01. The firm had revenue of $5.30 billion for the quarter, compared to analyst estimates of $5.29 billion. Abbott Laboratories had a net margin of 6.61% and a return on equity of 15.46%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.54 EPS. Equities research analysts anticipate that Abbott Laboratories will post $2.21 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 15th. Shareholders of record on Friday, January 13th will be paid a $0.265 dividend. This represents a $1.06 annualized dividend and a yield of 2.59%. The ex-dividend date of this dividend is Wednesday, January 11th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.26. Abbott Laboratories’s dividend payout ratio is currently 116.48%.
ILLEGAL ACTIVITY NOTICE: “Abbott Laboratories (ABT) Shares Sold by Henderson Group PLC” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at http://www.watchlistnews.com/abbott-laboratories-abt-shares-sold-by-henderson-group-plc/1061357.html.
Several brokerages have recently weighed in on ABT. Jefferies Group increased their price target on Abbott Laboratories to $47.00 and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. TheStreet downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 2nd. Bank of America Corporation reiterated a “buy” rating on shares of Abbott Laboratories in a report on Monday, September 19th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 price target on shares of Abbott Laboratories in a report on Monday, September 19th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Abbott Laboratories has an average rating of “Buy” and a consensus target price of $46.43.
In related news, Chairman Miles D. White acquired 121,456 shares of the company’s stock in a transaction on Thursday, November 10th. The shares were purchased at an average price of $40.45 per share, for a total transaction of $4,912,895.20. Following the purchase, the chairman now owns 2,802,558 shares in the company, valued at $113,363,471.10. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Robert B. Ford acquired 12,775 shares of the company’s stock in a transaction on Wednesday, December 14th. The stock was bought at an average price of $39.09 per share, for a total transaction of $499,374.75. Following the purchase, the insider now owns 51,532 shares in the company, valued at approximately $2,014,385.88. The disclosure for this purchase can be found here. 0.26% of the stock is currently owned by company insiders.
Abbott Laboratories Company Profile
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.